OncoMatch/Clinical Trials/NCT06940440
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Is NCT06940440 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including IFx-Hu2.0 and Pembrolizumab for advanced or metastatic merkel cell carcinoma.
Treatment: IFx-Hu2.0 · Pembrolizumab — This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to pembrolizumab in adult patients (≥18 years) with non-cutaneous Merkel Cell Carcinoma. Nine subjects will receive IFx-Hu2.0 as a visceral lesion injection in a single lesion followed by pembrolizumab.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Tumor Agnostic
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: checkpoint inhibitor (pembrolizumab, avelumab, ipilimumab, nivolumab)
no prior therapy with CPI including but not limited to Pembrolizumab, avelumab, ipilimumab, nivolumab
Cannot have received: systemic chemotherapy
Subjects who have received prior systemic chemotherapy
Lab requirements
Blood counts
adequate hematological function according to laboratory ranges and medical criteria defined within the study protocol
Kidney function
adequate renal function according to laboratory ranges and medical criteria defined within the study protocol
Liver function
adequate hepatic function according to laboratory ranges and medical criteria defined within the study protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida
- University of Wisconsin Carbone Cancer Center · Madison, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06940440 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior checkpoint inhibitor, systemic chemotherapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify